- Home
- LBTYA vs ARQT Comparison
LBTYA vs ARQT Comparison
Compare LBTYA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBTYA
- ARQT
- Stock Information
- Founded
- LBTYA 2004
- ARQT 2016
- Country
- LBTYA Bermuda
- ARQT United States
- Employees
- LBTYA N/A
- ARQT N/A
- Industry
- LBTYA Cable & Other Pay Television Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- LBTYA Telecommunications
- ARQT Health Care
- Exchange
- LBTYA Nasdaq
- ARQT Nasdaq
- Market Cap
- LBTYA 3.7B
- ARQT 3.3B
- IPO Year
- LBTYA N/A
- ARQT 2020
- Fundamental
- Price
- LBTYA $11.36
- ARQT $30.97
- Analyst Decision
- LBTYA Buy
- ARQT Strong Buy
- Analyst Count
- LBTYA 5
- ARQT 7
- Target Price
- LBTYA $14.96
- ARQT $22.17
- AVG Volume (30 Days)
- LBTYA 2.2M
- ARQT 2.7M
- Earning Date
- LBTYA 10-30-2025
- ARQT 10-28-2025
- Dividend Yield
- LBTYA N/A
- ARQT N/A
- EPS Growth
- LBTYA N/A
- ARQT N/A
- EPS
- LBTYA N/A
- ARQT N/A
- Revenue
- LBTYA $4,770,600,000.00
- ARQT $317,929,000.00
- Revenue This Year
- LBTYA $13.25
- ARQT $85.27
- Revenue Next Year
- LBTYA $1.75
- ARQT $30.70
- P/E Ratio
- LBTYA N/A
- ARQT N/A
- Revenue Growth
- LBTYA 170.50
- ARQT 129.21
- 52 Week Low
- LBTYA $9.03
- ARQT $10.57
- 52 Week High
- LBTYA $14.30
- ARQT $31.11
- Technical
- Relative Strength Index (RSI)
- LBTYA 60.38
- ARQT 75.88
- Support Level
- LBTYA $10.68
- ARQT $27.08
- Resistance Level
- LBTYA $11.14
- ARQT $31.10
- Average True Range (ATR)
- LBTYA 0.27
- ARQT 1.59
- MACD
- LBTYA 0.07
- ARQT 0.50
- Stochastic Oscillator
- LBTYA 96.00
- ARQT 98.36
About LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.